Introduction
Peripartum cardiomyopathy (PPCM) is an idiopathic form of cardiomyopathy, presenting with heart failure secondary to LV dysfunction towards the end of pregnancy or in the months following delivery, where no other cause of heart failure is identified.
1 Data on suspected or confirmed cases of PPCM from Europe and most other regions of the world are either non-existent or limited. 2, 3 It is therefore unknown whether PPCM occurs on all continents and if ethnicity or heterogeneous accesses to healthcare impacts on mode of presentation, management, and short-term (within 1 month post-diagnosis) maternal and foetal outcome.
The ongoing prospective, international, multicentre, observational registry aims to collect information on 1000 patients with PPCM, and is part of a rolling programme of surveys of different aspects of cardiovascular disease, as part of the EURObservational Research Programme (EORP) and as an initiative of the Study Group on PPCM of the Heart Failure Association. Data are collected not only in member countries of the ESC, but worldwide ( Figure 1) . The PPCM registry's overall primary objective is to describe the epidemiology, clinical characteristics, and outcome of in-and outpatients with PPCM, the diagnostic and therapeutic processes applied, and their impact on outcomes. The secondary objective is to evaluate how recommendations of recently published position papers on acute and chronic management of PPCM 2, 4 and the ESC Guidelines on cardiovascular disease in pregnancy as well as acute and chronic heart failure 5, 6 are currently followed. More specifically, information on the reasons for evidence-based treatments not being utilized, or prescribed at doses less than those recommended by guidelines, is collected. The registry will help to identify parameters which serve as diagnostic and prognostic markers-these may be useful for identification and risk stratification. Furthermore, information on mode of delivery and neonatal outcome will be collected. The project should lead to a better understanding of the disease and, subsequently, to practical recommendations on how the quality of care for patients with PPCM can be improved.
This first report summarizes the data on the presentation and initial management of the first 500 patients entered, to obtain information that can be used to improve diagnosis, clinical management, and service provision.
. 
Methods
Study design, patient selection, and data collection have been published. 2 Eligibility criteria for the centres were availability of echocardiography, advanced clinical care to make the diagnosis, and the possibility to follow the patients for at least 6 months and up to 5 years. Incident cases of consecutive patients per centre are entered into the database, and only patients diagnosed within 6 months of enrolment can be included. Data can be entered when available and in stages.
The case report form (CRF) for this ongoing registry can be accessed via the EORP website: www.eorp.org. A dedicated team of data specialists at the ESC Heart House is assisting physicians with entering cases and guidance in regulatory approval. The protocol, patient consent forms and study patient logs are provided on the website as pdf files. The front page contains mandatory key questions qualifying the patient as potential PPCM: (i) peripartum stage; (ii) signs and/or symptoms of heart failure; (iii) EF <45%; and (iv) other causes of heart failure are excluded. After all these points are checked, the next page opens with the registry data collection. This will ensure that only patients with PPCM will be entered. Follow-up will be requested at 6 months and, thereafter, 6 monthly for a total duration of a 5-year follow-up.
Standard management of patients will be the diagnostic and therapeutic interventions currently performed in each centre for patients presenting with signs and symptoms of PPCM. Drug prescriptions and indications to perform diagnostic/therapeutic procedures will be completely left up to the participating cardiologist's decision. No specific protocols or recommendations for evaluations, management, or treatment will be put forward during this observational study.
Data collected on enrolled patients and their offspring
The baseline visit was defined as the first visit to the specialist making the diagnosis of suspected PPCM supported by echocardiography. Data were collected, not only on the current visit/admission, but also on a previous episode of suspected cardiomyopathy/PPCM (one data field). Data collected include the demographic characteristics, risk factors for cardiovascular disease, pregnancy history, breast feeding pattern, data on familial cardiomyopathy, co-morbidities, clinical signs and symptoms, and blood tests performed. Mandatory echocardiography parameters include, besides LVEF, parameters of diastolic function, left atrial and LV dimensions, right ventricular function, and valvular abnormalities. As the diagnosis of PPCM is a diagnosis of exclusion, the final diagnosis could be modified after a more complete work-up was available and within 6 months of making the diagnosis.
Detailed information on non-pharmacological and pharmacological therapy initiated at the baseline visit/within 6-month follow-up is collected, including the names and doses of all cardiovascular drugs used, together with anticoagulation and the use of bromocriptine.
Data collected on participating sites
Key information on each participating site was also collected, including type of hospital, specialization of treating physician, and other parameters characterizing the set up available under which patients with PPCM could be assessed. 
Data recording, management, and data validation
Information was recorded via an electronic online CRF through a web-based data entry platform. The electronic CRF was developed by the Executive Committee. Core clinical data such as copy of ECG, copy of echocardiogram, and information of the foetus were validated via the central EORP office contacting the sites using a data monitor. recommended by the current guidelines and the PPCM echo manual. Furthermore, basic data will be collected 6 monthly for up to 5 years if patients and physicians consent to being part of the long-term follow-up arm.
Statistical analysis
Continuous variables were reported as mean ± SD or as median and interquartile range. Between-group comparisons were made by using a non-parametric test (Kruskal-Wallis test). Categorical variables were reported as percentages. Between-group comparisons were made by using a 2 test or a Fisher's exact test if any expected cell count was less than five. For categorical variables with more than two possible values, exact P-values have been estimated according to the Monte Carlo method.
A two-sided P-value <0.05 was considered statistically significant. All analyses were performed using SAS statistical software version 9.3 (SAS Institute, Inc., Cary, NC, USA).
Results
Between 1 August 2012 and 31 March 2016, 500 PPCM patients from 43 countries were entered into the registry (Supplementary material online, Figure S1 ). Baseline data on the first 411 patients with completed CRFs, as entered by 31 March 2016, are reported (see Appendix 1) . Figure 1 Figure 2 highlights the differences in socio-demographic parameters among studied regions, especially when separated between ESC and non-ESC countries: Human Development Index in PPCM patients from ESC (high: 65.5%) vs. non-ESC (high: 12.5%) countries (P < 0.001), GINI index on inequality in ESC (low: 83.7%) vs. non-ESC (low: 45.1%) countries (P < 0.001), and Health Expenditure in ESC (low: 0.0%) vs. non-ESC (low: 57.7%) countries (P < 0.001). A glossary is provided in the Supplementary material online, Table S1 . Despite the huge differences in socio-demographic factors among regions of the world, the baseline characteristics of PPCM patients such as obstetric history and clinical presentation were remarkably similar ( Table 1 ). The mode of presentation was also similar, mean age was 30.7 ± 6.4 years, mean gravidity 3.6 ± 1.9, and 22.8% had pre-eclampsia while pregnant. A total of 36.6% of PPCM patients were in NYHA functional class III, and 32.2% in class IV; mean systolic blood pressure was 118.8 ± 23.5 mmHg, and heart rate 100.7 ± 21.1 b.p.m. Two-thirds of patients presented after delivery (mostly within the first month post-partum) and one-third pre-partum ( Figure 3 ).
Differences were, however, seen between ESC and non-ESC countries: in the ESC countries, glucose levels were higher and smoking was more prevalent, while more patients were positive for HIV in the non-ESC countries. From the patients that presented with symptoms pre-partum in the non-ESC countries, 27.7% had a history of a cardiomyopathy diagnosed related to a previous pregnancy/PPCM, but only 10.3% in the ESC countries. Of the patients that presented pre-partum, 27 patients had a documented cardiomyopathy related to a previous pregnancy, with the majority having that diagnosis made post-partum (n = 23). Analysis separating patients with a cardiomyopathy diagnosed in a previous pregnancy and patients with HIV as a co-morbidity (n = 8) showed no difference between the groups (Supplementary material online, Table S2 ). The total number of months breastfeeding in all previous pregnancies was significantly different in ESC vs. non-ESC countries (P < 0.001).
. . . . . . . . . . . . . . . . . Table 2 describes the clinical variables and cardiac function at baseline. Mean LVEF was 32.2 ± 9.9% with an end-diastolic diameter of 60.3 ± 8.0 mm and end-systolic diameter of 50.0 ± 8.9 mm, and no significant differences were seen between studied regions. period due to heart failure (n = 6), stroke (n = 1), and sudden cardiac death (n = 3). Mean stay in the intensive care unit was 3.4 days, with no significant differences within ESC and non-ESC countries. Morbidity is very high, with the large majority of PPCM with symptomatic heart failure after 1 month (92.3% in non-ESC vs. 81.3% in ESC, P < 0.001). Implantation of a left ventricular assist device (LVAD) was performed in 3.0% of patients in ESC and 1.0% in non-ESC countries. Remarkably, venous thrombo-embolic events, arterial embolizations, as well as cerebrovascular accidents were common and documented in 28 of 411 cases (6.8%), with no difference between ESC and non-ESC countries. A total of 27.9% of patients in ESC countries received anticoagulant drugs vs. 15.9% in non-ESC countries (P = 0.022; Table 3 ). Figure 4 describes oral pharmacological management initiated if the patient was still pregnant ( Figure 4A ) or presenting post-partum ( Figure 4B ). Drug therapy initiated included diuretics (83.6%), ACE inhibitors (78.8%), beta-blockers (79.9%), and bromocriptine (21.2%), with significant differences in prescribing pattern of those medications in ESC vs. non-ESC countries (P < 0.001). While the use of ACE inhibitors/ARBs and mineralocorticoid receptor antagonists (MRAs) was similar in ESC vs. non-ESC countries, beta-blockers and ivabradine were used less frequently in non-ESC countries. In contrast, diuretics, digoxin, and bromocriptine were applied more frequently in PPCM patients from non-ESC countries.
Only a small minority of patients received a pacemaker, CRT, or an implantable cardioverter defibrillator in the early phase after diagnosis, with no differences in ESC vs. non-ESC countries.
Of note, neonatal outcome was available for 301 of the 402 cases who had a live birth (Supplementary material online, Table S3 ), with a neonatal death of 3.1% (n = 9).
Discussion
This large prospective international registry on PPCM thus far shows that the condition occurs in women from different ethnic backgrounds in all continents. Despite marked differences in . socio-economic background and ethnicity, the timing and mode of presentation were remarkably similar. We found that the short-term (1 month post-diagnosis) mortality was lower than expected while morbidity, including persistent dyspnoea, need for LVAD, and embolic events were common within 1 month post-diagnosis and required intensive, multidisciplinary management.
Geographic representation and mode of presentation
The epidemiology profile of PPCM is sparse, with most data coming from Nigeria and South Africa on the African continent, Haiti, and the USA. 7 -9 Recently a larger cohort study has been reported from Germany, 10 Japan, 11 and Turkey, 12 but reports from other European countries, the Middle East, Asia, and Australia remain absent or are single case reports. 7 Our data now reveal that PPCM occurs globally. As a large proportion of the cases only present with symptoms and signs of heart failure beyond the standard date of reporting of maternal death (<42 days post-partum), PPCM is likely to be under-reported as a cause of maternal death on a global scale.
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Mean age of presentation was relatively high, at 30.7 ± 6.4 years, and a parity of 3.1 ± 1.7, with no differences in ESC and non-ESC countries. Of the one-third of PPCM patients that presented pre-partum, 21% had a diagnosis of cardiomyopathy in a previous pregnancy, which was likely to be PPCM as 23 of the 27 patients presented only in the post-partum period. It is likely that the diagnosis of a previous PPCM had often been missed. Interestingly, in the non-ESC countries, 28% of these patients had a history of a previous cardiomyopathy, but only 10% in the ESC countries, which may be explained by the higher incidence of PPCM in Africa and some Asian areas. The percentage of previous cardiomyopathy is probably even higher as milder forms of PPCM are commonly missed. Those data demonstrate that women with a PPCM need a careful history recording, as pregnancy in a women with a previous PPCM has an increased risk of poor outcome. 
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Therapeutic management
Our data show significant differences in the initial management of patients with PPCM presenting while still pregnant or post-partum. Beta-blocker use was higher in ESC countries, whereas diuretic . . . . . . . . . . . . . use was higher in non-ESC countries when patients presented post-partum (P < 0.001). The reason for the significantly lower use of beta-blockers in non-ESC countries is unclear, as patients did not differ regarding NYHA class and EF. Beta-blockers are not only recommended as a class IA indication in all patients with heart failure with reduced EF, 6 but do appear to be of major importance for beneficial outcome in PPCM patients when given in addition to ACE inhibitors, as shown in the German PPCM registry.
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Bromocriptine was prescribed in 53 of 250 cases that received medication post-partum (21.2%), with significantly higher usage in non-ESC countries. Bromocriptine is postulated to have a key role of prolonged inhibition of a detrimental 16 kDa prolactin, leading to cardiac injury and dysfunction, and has been used in a pilot study in Africa 16 and in the majority of patients in the German multicentre registry. 15 Ivabradine was prescribed for 21 of 249 cases (8.4%), with a significantly higher usage in ESC countries. It is likely that prescription patterns are influenced by costs, as bromocriptine is available as a non-expensive generic in lower income countries whereas ivabradine, which has only recently been reported to be beneficial in acute PPCM, 17 will only be affordable in higher income countries.
Less than 5% of all patients received any form of device therapy in the acute management. Despite those marked differences in therapeutic management, there were no statistical differences in lenght of intensive care unit stay and mortality.
. 20 with >20% showing visible echocardiographic thrombus. This is likely to be linked to the hypercoagulable peripartum state, venous stasis, and vascular damage. 21 However, it is likely that many thrombi are not detected by routine echocardiography as, for example, left atrial appendage clots can be easily missed. This leads to the question of whether all patients with PPCM, particularly if EF is <35%, should receive anticoagulation for some time.
Neonatal outcome
The neonatal outcome of women with PPCM is rarely reported, as patients often presented several months post-partum. Information on neonates was available in 301 of the cases, with a reported neonatal death rate of 3.1%. 
Limitations
This is a registry organized and funded by the ESC. We have used the geographical and political definition of ESC vs. non-ESC as a group definition. This is a clear limitation for this analysis. However, we have collected and shown the data on ethnicity and income per patient diagnosed with PPCM in Table 1 and Figure 1 . This is an ongoing registry. We will analyse the data according to ethnic group and per country when we have reached the sample size of 1000.
A further limitation, as in all registries, is that only core information could be validated by monitors. Participation in the EORP registry is voluntary and unpaid. A certain selection bias for centres interested in this condition is likely and could explain better short-term outcome, as previously reported, due to better knowledge and subsequently multidisciplinary care.
Conclusions
This ongoing registry highlights the fact that much more data are needed regarding epidemiology, presentation, and management of PPCM globally. Much can be learned from such registries. Our data show that PPCM occurs with similar presentation mode independent of ethnic and socio-economic backgrounds. It remains a serious condition with a high rate of patients presenting critically, remaining in heart failure within 1 month post-diagnosis, and a substantial risk of embolic events. Therapeutic management differed substantially in ESC vs. non-ESC countries.
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